Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data

Maylene Wong, Lidia Staszewsky, Roberto Latini, Simona Barlera, Robert Glazer, Nora Aknay, Allen Hester, Inder Anand, Jay N Cohn

Research output: Contribution to journalArticlepeer-review

150 Scopus citations

Abstract

Objectives The objective of this study was to test the hypothesis that the severity of left ventricular remodeling predicts the response to treatment and outcomes in chronic heart failure. Background Reversal of remodeling should produce the most favorable outcome in patients with the most severe remodeling. Methods In 5,010 heart failure patients on background therapy and randomized to valsartan and placebo, serial recordings of left ventricular internal diastolic diameter (LVIDd) and ejection fraction (EF) were read at sites that had to meet qualifying standards before participating. Baseline LVIDd and EF were pooled across treatments and retrospectively grouped by quartiles Q1 to Q4, representing best to worst. Kaplan-Meier survival curves were obtained by the log-rank test. Q1 was compared with Q4 for mortality and combined mortality and morbidity (M + M) from Cox regression risk ratios (RRs). Valsartan versus placebo changes from baseline in LVIDd and EF were analyzed by quartiles from analysis of covariance. Valsartan and placebo were compared by RRs for M + M. Results Survival rates were greater in the better quartiles for LVIDd and EF (p < 0.00001). The RR for Q1 versus Q4 in events approached 0.5 for both LVIDd and EF (p < 0.0001). An LVIDd decrease and EF increase were quartile-dependent and greater with valsartan than placebo at virtually all time points. The RR for M + M outcomes favored valsartan in the worse quartiles. Conclusions Stratification by baseline severity of remodeling showed that patients with worse LVIDd and EF are at highest risk for an event, yet appear to gain the most anti-remodeling effect and clinical benefit with valsartan treatment.

Original languageEnglish (US)
Pages (from-to)2022-2027
Number of pages6
JournalJournal of the American College of Cardiology
Volume43
Issue number11
DOIs
StatePublished - Jun 2 2004

Keywords

  • ACE
  • ANCOVA
  • BB
  • EF
  • HF
  • LV
  • LVIDd
  • M + M
  • RR
  • analysis of covariance
  • angiotensin-converting enzyme
  • beta-blocker
  • combined mortality and morbidity
  • ejection fraction
  • heart failure
  • left ventricle/ ventricular
  • left ventricular internal diastolic diameter

Fingerprint Dive into the research topics of 'Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data'. Together they form a unique fingerprint.

Cite this